Ons 29 maj / År 42 / Nr 1 2024

Nanotechnology to go provided by GeccoDots

Imagine the opportunities a translational approach to advanced biomedical imaging could offer. Now add a complete toolbox for multipurpose imaging, combining widely used technologies such as MRI, PET and ultrasound. Finally, add a generous amount of novel contrast agents, optical probes, radionuclides and nanotechnology – and you will have the imaging technology of the future.

Nanotechnology opens up a new world of possibilities in many segments, not least in medical science. Nanotechnology is of particular interest applied to the development of new diagnostic tools and can thus help to discover new and more efficient treatments to various diseases. Essentially, nanotechnology can help us understand why these diseases occur and how to stop their generation altogether.

Nanotechnology enhances medical imaging
Medical imaging can be improved tremendously using nanotechnology. The Lund-based and research-oriented company GeccoDots has dedicated the past fifteen years to the development of multimodal contrast agents and biomarkers for medical imaging. By allowing users to mix and match while using the same agent, GeccoDots has created a translational approach to medical imaging, aiming to improve both diagnostics and treatments.
“Using nanotechnology, we have successfully created new contrast agents which can significantly enhance visibility inside of the human body. Our products make it possible for researchers to identify and follow disease progression like never before”, GeccoDots CEO Sarah Fredriksson explains.
What is interesting here is that the same contrast agent works regardless of imaging technology, thus considerably simplifying the imaging process.

Making the impossible possible
GeccoDots is a subsidiary wholly owned by Genovis. The name GeccoDots is a play of words inspired by the nanowires of a gecko’s feet, granting it unique properties of climbing and clinging on to flat surfaces. Just like in the case of the gecko, nanotechnology makes the seemingly impossible action fully possible even in medical science.
GeccoDots was founded to launch the nano-based contrast agents and to drive the development of next-generation products, which are now ready for market launch. Initially, the agents will be used in preclinical research, but there are no limits to what can be achieved using the next-generation contrast agent in combination with state-of-the-art imaging tools. Nanotechnology is the future of many industrial segments, life science clearly being one of them.